Cardioten  

Quick links to important sections

Cardioten  

Selected form

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cardioten  

Property Description
Active Ingredient Atenolol (INN)
Form Oral Tablet, Intravenous Injection
Pharmacological Class Beta-Adrenergic Receptor Blocking Agent
General Purpose Support for Cardiovascular Health
Origin Synthetic

What is Cardioten and What Type of Medicine is it?

Cardioten is a synthetic, prescription-only medication belonging to the beta-adrenergic receptor blocking agent class, commonly known as a beta-blocker. This classification means the drug modulates the body's natural signaling system involving catecholamines, providing a regulatory effect on heart activity. The generic component, Atenolol, is used for its sustained effectiveness in moderating cardiac output.

The active ingredient, Atenolol, is distinguished by its dose-dependent cardioselectivity; it primarily targets the beta-1 receptors concentrated in the heart muscle. This focused action is a key differentiating factor from older, non-selective agents. Furthermore, the core chemical entity is characterized by its relatively hydrophilic (water-soluble) nature, a property that leads to minimal hepatic metabolism, confirming that the body primarily relies on the renal system to eliminate the compound.


Composition, Origin, and Available Forms

Cardioten is provided in several pharmaceutical preparations, primarily as an oral tablet for long-term management. It is also supplied as a sterile aqueous solution for intravenous injection for use in acute settings. While typically a single-agent product, the active ingredient is also available in combination formulations designed to leverage additive effects with other anti-hypertensive agents.


General Purpose and How it Supports Cardiovascular Health

The fundamental purpose of Cardioten is to achieve a controlled, long-term moderation of the heart's function and workload. By competitively blocking stimulating hormones, Cardioten effectively slows the heart rate (negative chronotropic action) and gently reduces the force of its contractions (negative inotropic action). The drug’s core therapeutic goal is to stabilize and support cardiovascular health by decreasing the heart's demand for oxygen and alleviating physical strain on the circulatory system.

What side effects are possible with Cardioten  ?

Possible Side Effects and Safety Information

Cardioten has an established safety profile based on clinical trial and regulatory data, with potential adverse reactions primarily affecting the cardiovascular and nervous systems.

Common Adverse Reactions

Adverse reactions reported in clinical trials occurring in 4% or more of patients include:

System-Organ Class Preferred Term Incidence
Nervous System Headache 15%
Cardiovascular Hypotension 6%
Gastrointestinal Nausea/Vomiting 5%
Cardiovascular Tachycardia 4%

Serious and Clinically Significant Risks

Cardioten is strictly contraindicated in patients with advanced aortic stenosis. This restriction is due to the drug's mechanism potentially worsening the myocardial oxygen balance in this specific cardiac condition.

Induction or exacerbation of angina (chest pain) has been reported in less than 1% of patients with coronary artery disease who received the treatment. Additionally, safety documents caution against the risk of venous thrombosis, phlebitis, and vascular impairment related to the infusion site, recommending the avoidance of small peripheral veins.

Population-Specific Safety Considerations

  • Pregnancy: Based on available animal data, Cardioten may cause fetal harm when administered to a pregnant patient.
  • Pediatric Use: The safety and effectiveness of the drug have not been established in patients under 18 years of age.
  • Organ Impairment: Patients with impaired hepatic function or renal impairment require close monitoring. In patients with moderate renal impairment, a significantly lower systemic clearance has been observed, indicating a potential for prolonged drug effects.

Blood pressure and heart rate should be monitored continually during Cardioten administration to manage the risk of rapid or excessive drops in blood pressure or heart rate changes.

Overdose and Emergency Response

Overdose and when to seek help

The information regarding Cardioten (Atenolol) overdose is strictly based on official regulatory documentation and outlines specific physiological effects and emergency actions.

Documented Overdose Manifestations

Official labeling indicates that an overdose may present with severe manifestations primarily affecting the cardiovascular and central nervous systems. Cardiovascular signs include marked bradycardia (slow heart rate), hypotension (low blood pressure), and sinus pause. Central Nervous System effects documented are lethargy, confusion, drowsiness, convulsions, and coma. Respiratory distress, such as bronchospasm, and metabolic findings, including hypoglycemia (low blood sugar), are also documented.


Regulatory Mandates for Emergency Action

An overdose is officially classified as potentially very dangerous, with the risk of progressing to cardiogenic shock or cardiac failure. For this reason, regulatory guidance explicitly requires individuals to seek immediate medical help right away and contact emergency services upon suspected overdose. Hospital monitoring is mandated due to the severity of potential complications. It is officially stated that no specific antidote is known for Atenolol overdose; therefore, management is based on symptomatic and supportive treatment, including procedures like gastric lavage or hemodialysis as documented in the prescribing information.

Therapeutic Uses of Cardioten  

What Cardioten Treats: Main Uses and Benefits

Cardioten (Atenolol) is a medication generally used in therapeutic domains related to cardiovascular stability and the management of symptoms related to heightened physiological activity. It is relevant for easing symptoms and providing support across several key conditions marked by increased physiological stress.


Therapeutic Scope and Patient Benefit

The medication is commonly used to help with the long-term stabilization of essential hypertension (high blood pressure) and for the prophylactic management of Angina Pectoris (chest pain). Furthermore, it is applied to manage symptoms that create noticeable physiological strain arising from heart rate fluctuations, such as rapid heart rate (tachycardia) and disruptive palpitations associated with cardiac arrhythmias. In contextual uses, it provides symptomatic support for conditions like thyrotoxicosis and supportive relief for essential tremor, and is considered relevant for preventative relief against recurrent episodes like migraine headaches.

“This medication is commonly used to help patients cope more steadily with symptom fluctuations, contributing to improved comfort during symptomatic periods.”

In situations involving chronic cardiovascular strain, this medication provides sustained therapeutic support that may help lower the risk of severe complications and is considered relevant for supporting the patient during post-heart attack recovery. Its use contributes to easing the overall symptom load, assisting with maintaining functional stability in daily life.


Quick Fact: Relief for Heightened Heart Activity Cardioten supports patients by addressing symptoms of increased neurological or muscular activity, making it relevant in clinical settings that involve acute or unstable symptom patterns.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Scope

Category Official Regulatory Status
Populations Allowed Adult patients for approved indications (e.g., Essential Hypertension, Angina Pectoris).
Use Not Recommended Pediatric population; safety and efficacy have not been established.
Contraindicated Sinus Bradycardia, Second- or Third-Degree Heart Block, Cardiogenic Shock, Overt Cardiac Failure, Metabolic Acidosis, and Untreated Pheochromocytoma.

Age and Condition-Specific Eligibility

Category Official Regulatory Status
Age-related rules Older adults may require reduced dosage due to potential impaired renal function.
Renal Function Use requires mandatory dosage adjustment when Creatinine Clearance is low.
Pregnancy/Lactation Caution is advised; use may be associated with fetal growth restriction and risk of infant bradycardia/hypoglycemia due to milk excretion.
Eligibility Restrictions Caution is required in patients with Diabetes Mellitus (risk of masking hypoglycemia symptoms) and Severe Bronchial Asthma.

Connection to the Overall Eligibility Profile

The official eligibility profile strictly defines patient groups who can or cannot use the medicine by categorizing constraints across key physiological domains, primarily based on the patient's cardiac conduction status and renal capacity, establishing absolute bans and conditional use restrictions.

What should I know about interactions with other medicines?

Cardioten Interactions with Other Medicines and Products

This section outlines the officially documented interaction patterns for Cardioten (Atenolol) as described in government regulatory prescribing information.


Formally Contraindicated Combinations

The concomitant intravenous use of Verapamil or Diltiazem is formally contraindicated due to the risk of severe cardiac depression, including profound hypotension and bradycardia. Furthermore, regulatory guidelines specify that neither Cardioten nor the calcium channel blocker should be administered intravenously within 48 hours of discontinuing the other.


Documented Pharmacodynamic Interactions

Interactions often involve additive effects on heart rate, conduction, or blood pressure. Co-administration with certain agents may require close observation, as detailed in the official product labeling:

  • Calcium Channel Blockers (e.g., Nifedipine) and Catecholamine-Depleting Drugs (e.g., Reserpine) increase the risk of hypotension and/or marked bradycardia.
  • Class I Anti-arrhythmic Drugs (e.g., Disopyramide) and Digitalis Glycosides may potentiate effects on atrial conduction time.
  • Insulin and Oral Antidiabetic Drugs may have their blood sugar-lowering effects intensified by Cardioten.
  • Prostaglandin Synthetase Inhibiting Drugs (e.g., Indomethacin) may decrease Cardioten’s hypotensive effect.

Other Specific Interaction Constraints

Regulatory documents mandate that Cardioten should be withdrawn several days before the gradual withdrawal of Clonidine to prevent rebound hypertension. Additionally, since Atenolol is primarily cleared by the kidneys, its effects may be increased in patients with renal impairment or in the elderly due to slower elimination.

Mechanism of Action

Cardioten is a cardiotonic steroid, a compound that selectively targets the sodium-potassium adenosine triphosphatase (Na^+/K^+-ATPase) enzyme located on the plasma membrane of cardiomyocytes and other cells. The compound acts as a non-competitive inhibitor of the enzyme, binding to a specific extracellular site on the alpha-subunit of the Na^+/K^+-ATPase. This interaction reduces the enzyme's capacity to transport three Na^+ ions out of the cell in exchange for two K^+ ions into the cell. The inhibition of Na^+/K^+-ATPase activity causes a progressive increase in intracellular Na^+ concentration. The elevated intracellular Na^+ gradient consequently reduces the driving force for the Na^+/Ca^2+ exchanger (NCX), a secondary active transporter that normally exports one Ca^2+ ion in exchange for three Na^+ ions entering the cell. The resultant reduction in Ca^2+ efflux across the sarcolemma leads to a net accumulation of Ca^2+ within the myocyte's sarcoplasmic reticulum. The increase in intracellular and stored Ca^2+ subsequently facilitates enhanced Ca^2+ binding to troponin C during the excitation-contraction coupling cycle. The system-level physiological consequence of this intracellular cascade is a direct modulation of myocardial contractility, characterized by increased force generation during systole.

Dosage and Administration Information

How to use Cardioten — Administration Guidelines

This section describes the administration and dosing guidelines for Cardioten (Atenolol), based on prescribing information.

Route of Administration: Oral tablet for chronic maintenance and Intravenous injection for early intervention in acute settings.
Dosing Schedule (Regimens): Hypertension treatment typically starts with 50 mg once daily; the maximum effective dose is generally 100 mg once daily. For Angina Pectoris, a daily dose of 100 mg may be taken as a single tablet or divided into 50 mg doses twice daily.
Timing in Relation to Meals: Oral tablets may be taken with or without food; patients are advised to maintain a consistent routine for daily administration.
Preparation Requirements: The oral tablets should be swallowed whole with water. The intravenous form, used in acute care, requires administration as a slow injection at a specified rate.
Age-Group and Condition Rules: Older adults may require an initial starting dose of 25 mg. Mandatory dosage adjustments are necessary for patients with impaired renal function (Creatinine Clearance < 35 mL/min); for example, the maximum dose is restricted within that range. Safety and efficacy for the pediatric population are not established.
Missed-Dose Rules: If a dose is missed and the time for the next scheduled dose is approaching, the missed dose should be skipped entirely; a double dose must not be taken.
Special Procedural Conditions: Chronic therapy must be discontinued by gradually reducing the dose over a period of 7 to 14 days, not abruptly. Dialysis patients receive a dose (e.g., 50 mg) orally after each dialysis session under supervision.

Resulting Procedural Structure

The use protocol separates the administration into two primary patterns: Oral/Daily for chronic management and Intravenous/Sequential for immediate acute intervention. The protocol defines not only the numerical doses but also the necessary modifications for patients with reduced kidney function and the procedural requirement for a gradual reduction in dosage if treatment is to be stopped.

Recent Clinical Evidence

Research evidence / Overview of Studies for Cardioten (Atenolol)

The following summary describes the type of clinical research that has been conducted on Cardioten (Atenolol). It outlines the focus of major studies and the areas where scientific certainty remains low, based on official regulatory and peer-reviewed sources.


Evidence for Use in Essential Hypertension (High Blood Pressure)

Research exploring Cardioten was studied for high blood pressure, and this included both large-scale Randomized Controlled Trials (RCTs) and comprehensive meta-analyses. Outcomes measured included patterns of measured change in Systolic and Diastolic Blood Pressure (BP), and the subsequent occurrence of major events such as Stroke and Myocardial Infarction (heart attack). Studies reported patterns of measured change in BP values across the observed populations. Certain analyses reported observations regarding the incidence of combined cardiovascular events and stroke when compared to a placebo or no treatment. What remains uncertain is whether long-term outcomes are different when compared to other treatments studied for uncomplicated hypertension, and evidence for certain subgroups remains heterogeneous.


Evidence for Use in Angina Pectoris (Chest Pain)

For Angina Pectoris, the evidence relies significantly on RCTs that monitored outcomes related to physical discomfort, specifically measuring the frequency of chest pain episodes reported by patients. Research also explored outcomes reflecting daily functioning or activity level, such as monitoring changes in a patient's exercise capacity. Studies exploring short-term symptom changes reported observations of a decrease in the documented frequency of anginal attacks and an increase in measured exercise duration.


Evidence for Use in Post-Heart Attack Recovery

Cardioten was studied for use in the acute phase and for secondary prevention following a myocardial infarction (heart attack). Research for this use includes large-scale RCTs that specifically evaluated outcomes such as All-cause Mortality and the incidence of Recurrent Heart Attacks. Studies conducted during the acute phase was studied for differences in measured mortality rates in the treated patient groups compared to controls. Research data show patterns related to the rate of recurrent cardiac events during the follow-up period. Comparative evidence is lacking to definitively establish the relative long-term outcome of Cardioten over other specific beta-blockers now commonly studied for patients with post-MI situations.

Key Studies & References

  1. Atenolol: Uses, How to Take, Side Effects, Warnings (FDA/General Prescribing Information)

Frequently Asked Questions (FAQ)

Common questions about Cardioten (FAQ)


Q: Can Cardioten cause weight gain, or is that just a myth?

Regulatory information indicates that weight gain is a potential side effect sometimes reported with older types of beta-blockers, which includes the active ingredient in Cardioten. This change in weight is typically small and is more commonly observed during the first few months after starting treatment.


Q: Will Cardioten make me feel tired or fatigued?

Yes, unusual tiredness or weakness (fatigue) is reported as a common side effect in clinical trial data for Cardioten. Studies show that a significant portion of patients may experience this. Patients are generally advised to be mindful of this effect.


Q: What are the most common reasons a doctor would choose Cardioten over other options?

Official information highlights that Cardioten's active ingredient is distinguished by its cardioselectivity, meaning it primarily targets the receptors concentrated in the heart. Additionally, it is noted for its low lipid solubility, which means it is minimally processed by the liver and primarily eliminated by the kidneys. These properties can influence a healthcare professional's prescribing choice.


Q: What does the long-term research say about using Cardioten?

Long-term studies have been conducted on Cardioten for conditions like high blood pressure and post-heart attack recovery. This research evaluated its effectiveness in reducing the risk of major cardiovascular events like stroke and heart attack over time. The drug is generally effective for a full 24 hours after a single dose.


Q: Does Cardioten affect a person's mood or cause anxiety?

Yes, official data reports that Cardioten can have effects on the central nervous system. Adverse effects on mood, including depression and lethargy, have been reported. Sleep disturbances, such as insomnia and nightmares, have also been noted in clinical data.


Q: Can Cardioten cause dry cough, or is that a side effect of other types of heart meds?

A cough is listed as a less common side effect in some product monographs for Cardioten. Official information also cautions that the drug is generally not recommended for use in patients who have a history of conditions like asthma or wheezing.


Q: Is Cardioten considered a 'statin' or a different class of drug?

Cardioten is not a statin. According to official classification, it is a beta-adrenergic receptor blocking agent, commonly known as a beta-blocker. Statins are a different class of drugs used specifically to lower cholesterol.


Q: Does Cardioten have any known interactions with alcohol?

Official information indicates that alcohol may have an additive effect when combined with Cardioten. This combination can increase the potential for the blood pressure to drop too low, potentially causing symptoms like lightheadedness or dizziness.


Q: Is it normal to have mild headaches when first taking Cardioten?

Headache is a common adverse reaction, with clinical trials reporting it in up to 15% of patients. Official product information lists this as a frequent event, but it does not specify if this symptom is temporary or expected only at the start of therapy.


Q: What should I do if I notice a change in my heart rate after starting Cardioten?

Cardioten is expected to slow the heart rate. Patient information advises that changes in heart rate that feel too slow, uneven, or are accompanied by lightheadedness should be discussed with a healthcare professional. The drug is contraindicated in certain severe heart rhythm conditions.


Q: Are there any specific foods to avoid when using Cardioten?

Regulatory information states the tablets can be taken with or without food. However, some clinical data suggests that avoiding large amounts of orange juice may be necessary, as it might potentially decrease the effectiveness of the medicine.


Q: Is Cardioten used for heart failure, or just high blood pressure?

Cardioten is approved and studied for high blood pressure (hypertension) and a type of chest pain called angina pectoris. However, it is strictly contraindicated (should not be used) in patients who have overt or uncontrolled heart failure.


Q: Are there generic versions of Cardioten available?

Yes, Cardioten is the brand name for the active ingredient Atenolol. The generic version, Atenolol, is widely available as an oral tablet.


Q: Does Cardioten affect cholesterol levels?

Official information acknowledges that Cardioten, like other beta-blockers, may cause alterations in serum lipid profiles (fats in the blood). These changes can include potential increases in VLDL and LDL cholesterol and triglycerides, and a decrease in HDL cholesterol.


Q: Is it true that Cardioten can help protect against stroke?

Clinical studies for Cardioten used in high blood pressure measured the occurrence of major events, including stroke. While lowering high blood pressure is a key strategy for reducing stroke risk, the product information reports observations regarding the incidence of stroke but does not make a specific claim about the level of protection.


Q: Can children or adolescents be prescribed Cardioten?

According to official regulatory documents, the safety and effectiveness of Cardioten have not been established in patients under 18 years of age. Therefore, the drug is not approved for use in the pediatric population.


Q: What is the purpose of the different strengths of Cardioten tablets?

Cardioten is available in several strengths (e.g., 25 mg, 50 mg, 100 mg) to provide flexibility in treatment. This allows a healthcare professional to start treatment at a lower initial dose and make adjustments as needed, such as for patients with impaired kidney function.


Q: Can Cardioten cause swelling in the ankles or legs?

Swelling of the ankles or lower legs is noted as an uncommon side effect in patient information leaflets. This symptom is also a sign related to worsening heart failure, a condition where Cardioten is generally not recommended.


Q: Are there known allergic reactions to Cardioten?

Yes, Cardioten is contraindicated (should not be used) in individuals who have a known hypersensitivity or allergic reaction to the active ingredient (atenolol). Reactions such as hives (urticaria) and angioedema (swelling beneath the skin) have been reported.


Q: What makes Cardioten a 'cardiovascular' medicine?

Cardioten is classified as a cardiovascular medicine because its principal action is focused on the heart and circulatory system. It is a beta-1 selective beta-blocker, which means it specifically modulates the beta-adrenergic receptors concentrated in the heart muscle to regulate its function.


Q: Is Cardioten a pill, a capsule, or available in different forms?

Cardioten is supplied in two main forms. It is primarily available as an oral tablet for long-term daily management. It is also supplied as a sterile aqueous solution for intravenous injection for use in acute hospital settings.


Q: How quickly am I supposed to feel the effects of Cardioten?

Studies indicate that a significant effect on the heart is usually noticeable within one hour after taking an oral dose. However, the full blood pressure-lowering effect typically requires longer, with the maximum benefit generally seen after one to two weeks of consistent treatment.


Q: Is it common to feel a little dizzy when starting Cardioten?

Dizziness is listed as a common side effect in the official product information. This effect is often associated with the drug's action of lowering blood pressure. Dizziness can also manifest as lightheadedness or faintness when changing position too quickly.


Q: Does Cardioten interact badly with common pain relievers like ibuprofen?

Yes, regulatory information indicates that Nonsteroidal Anti-inflammatory Drugs (NSAIDs), such as ibuprofen, may reduce the blood pressure-lowering activity of Cardioten. This means that combining them could potentially decrease the drug’s effectiveness.


Q: Can I take Cardioten with my vitamins and supplements?

Official information advises caution regarding certain supplements. Specifically, taking Cardioten with multivitamins that contain minerals may decrease the overall effectiveness of the drug. A separation of at least two hours between taking the drug and the supplement is sometimes suggested in clinical context.


Q: What kind of monitoring (blood tests, etc.) is needed while on Cardioten?

Close monitoring is required, especially for patients with impaired kidney function, as the dose may need mandatory adjustment. For all patients, blood pressure and heart rate should be continually monitored to manage the risk of them dropping too low.


Q: What should be done if Cardioten seems to stop working after a while?

If the intended effect is no longer being achieved, official documents suggest that the next step in the standard protocol is re-evaluation, which may involve dose adjustment by a healthcare professional.


Q: Can Cardioten affect athletic performance or exercise tolerance?

Yes, studies have shown that Cardioten can reduce the exercise-induced increase in heart rate. Research on patients with angina measured changes in exercise capacity, which suggests the drug has an effect on the body's tolerance for physical activity.


Q: What is the typical timeframe before Cardioten starts to fully control symptoms?

The full therapeutic effect, or the typical timeframe before the drug starts to fully control symptoms, is observed within one to two weeks after beginning treatment with a consistent dose.


Q: Why do doctors recommend taking Cardioten at the same time every day?

Regulatory documents indicate the drug is effective for at least 24 hours. Taking the drug consistently at the same time helps ensure the concentration of the medicine in the blood remains stable throughout the day and night, supporting a sustained therapeutic effect.


How should Cardioten &nbsp; be stored and disposed of?

Cardioten (atenolol) tablets must be stored at Controlled Room Temperature, which is defined by regulatory documents as 20°C to 25°C (68°F to 77°F), with excursions allowed up to 30°C. The medication requires protection from light and must be kept away from excess heat, moisture, and freezing conditions.

Storage and Protection

The tablets must be dispensed and maintained in a tight, light-resistant container. To prevent accidental ingestion, Cardioten must always be stored out of the sight and reach of children.

Disposal

To dispose of unused or expired Cardioten, official guidance recommends utilizing a drug take-back program. If a take-back option is unavailable, the product should be mixed with an unappealing substance, sealed in a bag, and disposed of in household trash; it must not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cardioten &nbsp; found in:

A-Z Index: